Jeffrey S. Scehnet
University of Southern California
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeffrey S. Scehnet.
Blood | 2008
Alexandre Trindade; S. Ram Kumar; Jeffrey S. Scehnet; Luís Lopes-da-Costa; Jörg D. Becker; Weidong Jiang; Ren Liu; Parkash S. Gill; Antonio Duarte
The importance of Notch signaling pathway in the regulation of vascular development and angiogenesis is suggested by the expression of Notch receptors and ligands in vascular endothelial cells (ECs) and the observed vascular phenotypes in mutants of Notch receptors or ligands, especially Dll4. DLL4 is specifically expressed in arterial ECs during development, and haplo-insufficiency is embryonically lethal in mice. To address the role of Dll4 in vascular development, we produced mDll4 conditionally overexpressed transgenic mice that were crossed with constitutive recombinase cre lines. Double transgenic embryos displayed grossly enlarged dorsal aortae (DA) and died before embryonic day 10.5 (E10.5), showing a variable degree of premature arteriovenous fusion. Veins displayed ectopic expression of arterial markers. Other defects included reduced vascular sprouting, EC proliferation, and migration. mDll4 overexpression also inhibited VEGF signaling and increased fibronectin accumulation around the vessels. In vitro and in vivo studies of DLL4-FL (Dll4-full-length) in ECs recapitulate many of the mDll4 transgenics findings, including decreased tube formation, reduced vascular branching, fewer vessels, increased pericyte recruitment, and increased fibronectin expression. These results establish the role of Dll4 in arterial identity determination, and regulation of angiogenesis subject to dose and location.
Cancer Research | 2009
S. Ram Kumar; Jeffrey S. Scehnet; Eric J. Ley; Jasbir Singh; Valery Krasnoperov; Ren Liu; Parmeet K. Manchanda; Robert D. Ladner; Debra Hawes; Fred A. Weaver; Robert W. Beart; Gagandeep Singh; Cu Nguyen; Michael Kahn; Parkash S. Gill
The receptor tyrosine kinase EphB2 is expressed by colon progenitor cells; however, only 39% of colorectal tumors express EphB2 and expression levels decline with disease progression. Conversely, EphB4 is absent in normal colon but is expressed in all 102 colorectal cancer specimens analyzed, and its expression level correlates with higher tumor stage and grade. Both EphB4 and EphB2 are regulated by the Wnt pathway, the activation of which is critically required for the progression of colorectal cancer. Differential usage of transcriptional coactivator cyclic AMP-responsive element binding protein-binding protein (CBP) over p300 by the Wnt/beta-catenin pathway is known to suppress differentiation and increase proliferation. We show that the beta-catenin-CBP complex induces EphB4 and represses EphB2, in contrast to the beta-catenin-p300 complex. Gain of EphB4 provides survival advantage to tumor cells and resistance to innate tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death. Knockdown of EphB4 inhibits tumor growth and metastases. Our work is the first to show that EphB4 is preferentially induced in colorectal cancer, in contrast to EphB2, whereby tumor cells acquire a survival advantage.
American Journal of Pathology | 2010
Valery Krasnoperov; S. Ram Kumar; Eric J. Ley; Xiuqing Li; Jeffrey S. Scehnet; Ren Liu; Sergey Zozulya; Parkash S. Gill
EphB4 receptor tyrosine kinase and its cognate ligand EphrinB2 regulate induction and maturation of newly forming vessels. Inhibition of their interaction arrests angiogenesis, vessel maturation, and pericyte recruitment. In addition, EphB4 is expressed in the vast majority of epithelial cancers and provides a survival advantage to most. Here, we describe two anti-EphB4 monoclonal antibodies that inhibit tumor angiogenesis and tumor growth by two distinct pathways. MAb131 binds to fibronectin-like domain 1 and induces degradation of human EphB4, but not murine EphB4. MAb131 inhibits human endothelial tube formation in vitro and growth of human tumors expressing EphB4 in vivo. In contrast, MAb47 targets fibronectin-like domain 2 of both human and murine EphB4 and does not alter EphB4 receptor levels, but inhibits angiogenesis and growth of both EphB4-positive and EphB4-negative tumors in a mouse s.c. xenograft model. Combination of MAb47 and bevacizumab enhances the antitumor activity and induces tumor regression. Indeed, humanized antibodies hAb47 and hAb131 showed similar affinity for EphB4 and retained efficacy in the inhibition of primary tumor development and experimental metastasis.
Blood | 2009
Jeffrey S. Scehnet; Eric J. Ley; Valery Krasnoperov; Ren Liu; Parmeet K. Manchanda; Eric Sjoberg; Anna P. Kostecke; Sachin Gupta; S. Ram Kumar; Parkash S. Gill
Kaposi sarcoma (KS) is associated with human herpesvirus (HHV)-8 and is dependent on the induction of vascular endothelial growth factors (VEGFs). VEGF regulates genes that provide arterial or venous identity to endothelial cells, such as the induction of EphrinB2, which phenotypically defines arterial endothelial cells and pericytes, and represses EphB4, which defines venous endothelial cells. We conducted a comprehensive analysis of the Eph receptor tyrosine kinases to determine which members are expressed and therefore contribute to KS pathogenesis. We demonstrated limited Eph/Ephrin expression; notably, the only ligand highly expressed is EphrinB2. We next studied the biologic effects of blocking EphrinB2 using the extracellular domain of EphB4 fused with human serum albumin (sEphB4-HSA). sEphB4-HSA inhibited migration and invasion of the KS cells in vitro in response to various growth factors. Finally, we determined the biologic effects of combining sEphB4-HSA and an antibody to VEGF. sEphB4-HSA was more active than the VEGF antibody, and combination of the 2 had at least additive activity. sEphB4-HSA reduced blood vessel density, pericyte recruitment, vessel perfusion, and increased hypoxia, with an associated increase in VEGF and DLL4 expression. The combination of sEphB4-HSA and VEGF antibody is a rational treatment combination for further investigation.
Blood | 2010
Ren Liu; Xiuqing Li; Anil Tulpule; Yue Zhou; Jeffrey S. Scehnet; Shaobing Zhang; Jong-Soo Lee; Preet M. Chaudhary; Jae Jung; Parkash S. Gill
Kaposi sarcoma-associated herpesvirus (KSHV) infection is essential to the development of Kaposi sarcoma (KS). Notch signaling is also known to play a pivotal role in KS cell survival and lytic phase entrance of KSHV. In the current study, we sought to determine whether KSHV regulates Notch components. KSHV-infected lymphatic endothelial cells showed induction of receptors Notch3 and Notch4, Notch ligands Dll4 and Jagged1, and activated Notch receptors in contrast to uninfected lymphatic endothelial cells. In addition, KSHV induced the expression of endothelial precursor cell marker (CD133) and mural cell markers (calponin, desmin, and smooth muscle alpha actin), suggesting dedifferentiation and trans-differentiation. Overexpression of latency proteins (LANA, vFLIP) and lytic phase proteins (RTA, vGPCR, viral interleukin-6) further supported the direct regulatory capacity of KSHV viral proteins to induce Notch receptors (Notch2, Notch3), ligands (Dll1, Dll4, Jagged1), downstream targets (Hey, Hes), and endothelial precursor CD133. Targeting Notch pathway with gamma-secretase inhibitor and a decoy protein in the form of soluble Dll4 inhibited growth of KSHV-transformed endothelial cell line. Soluble Dll4 was also highly active in vivo against KS tumor xenograft. It inhibited tumor cell growth, induced tumor cell death, and reduced vessel perfusion. Soluble Dll4 is thus a candidate for clinical investigation.
Blood | 2007
Jeffrey S. Scehnet; Weidong Jiang; S. Ram Kumar; Valery Krasnoperov; Alexandre Trindade; Rui Benedito; Dusan Djokovic; Cristina Borges; Eric J. Ley; Antonio Duarte; Parkash S. Gill
The International Journal of Developmental Biology | 2004
Ping Wu; Lianhai Hou; Maksim V. Plikus; Michael W. Hughes; Jeffrey S. Scehnet; Sanong Suksaweang; Randall B. Widelitz; Ting Xin Jiang; Cheng-Ming Chuong
American Journal of Pathology | 2006
S. Ram Kumar; Jasbir Singh; Guangbin Xia; Valery Krasnoperov; Loubna Hassanieh; Eric J. Ley; Jeffrey S. Scehnet; Neil G. Kumar; Debra Hawes; Michael F. Press; Fred A. Weaver; Parkash S. Gill
Archive | 2013
Ren Liu; Parkash Gill; Antonio Duarte; Alexandre Trindade; S. Ram Kumar; Jeffrey S. Scehnet; Luís Lopes-da-Costa; Jörg D. Becker
Archive | 2009
Ren Liu; Parkash Gill; Antonio Duarte; Alexandre Trindade; S. Ram Kumar; Jeffrey S. Scehnet; Luís Lopes-da-Costa; Jörg D. Becker